SCHEMBL12523006

SCHEMBL12523006

BCO[C@H](CO)C1COC(C)(C)O1

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28595771 0.81 CA2 (0.33) CA2
SCHEMBL11114168 0.81 CA2 (0.33) CA2
SCHEMBL15445567 0.80 CA2 (0.32) CA2
SCHEMBL26122735 0.73 L3MBTL1 (0.37) CA2
SCHEMBL26122737 0.73 L3MBTL1 (0.37) CA2
SCHEMBL26122739 0.73 L3MBTL1 (0.37) CA2
SCHEMBL12540514 0.72 CA2 (0.32) CA2
SCHEMBL11961355 0.72 CA2 (0.32) CA2
SCHEMBL8910610 0.72 CA2 (0.32) CA2
SCHEMBL16371103 0.72 CA2 (0.32) CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120237480-A1 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2012-09-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120237480-A1 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES NME2, HAVCR2, ENTPD5 CA2 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback